/DSGN
DSGN Stock - Design Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$9.68+7.44%
+$0.67 (+7.44%) • Dec 19
81
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.54
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+49.8%upside
Target: $14.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for DSGN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$9.58 – $9.78
TARGET (TP)$14.50
STOP LOSS$8.91
RISK/REWARD1:6.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.64
52W High$10.31
52W Low$2.60
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-596,000 | $-537,000 | $-466,000 | N/A | $-5,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-62,383,000 | $-78,190,000 | $-67,593,000 | $-35,831,000 | $-8,556,000 |
| Net Income | $-49,588,000 | $-66,862,000 | $-63,308,000 | $-35,533,000 | $-8,280,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.88 | $-1.19 | $-1.14 | $-0.77 | $-0.30 |
Company Overview
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
63%
Hold / Neutral
3
38%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
5 Bullish3 Neutral/Bearish
Price Targets
$12
Average Target
↑ 27.7% Upside
Now
$6
Low
$12
Average
$30
High
Based on 11 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 3rd 2025 | Craig Hallum | Initiation | Buy | $15 |
| December 3rd 2025 | Leerink Partners | Upgrade | Outperform | $14 |
| November 20th 2025 | RBC Capital Mkts | Upgrade | Outperform | $13 |
| May 7th 2024 | Piper Sandler | Upgrade | Overweight | $12← $6 |
| November 14th 2023 | Piper Sandler | Downgrade | Neutral | $6← $42 |
| August 15th 2023 | Wedbush | Downgrade | Neutral | $6← $19 |
| August 15th 2023 | RBC Capital Mkts | Downgrade | Sector Perform | $7← $23 |
| August 15th 2023 | SVB Securities | Downgrade | Market Perform | $6 |
| May 4th 2023 | Goldman | Upgrade | Neutral | $6 |
| June 10th 2022 | Wedbush | Initiation | Outperform | $21 |
| May 2nd 2022 | RBC Capital Mkts | Initiation | Outperform | $30 |
Earnings History & Surprises
DSGNBeat Rate
67%
Last 18 quarters
Avg Surprise
+6.1%
EPS vs Estimate
Beats / Misses
12/6
Last 12 quarters
Latest EPS
$-0.30
Q4 2025
EPS Surprise History
Q1 24
+34.4%
$-0.21vs$-0.32
Q2 24
+28.6%
$-0.20vs$-0.28
Q3 24
+16.0%
$-0.21vs$-0.25
Q4 24
+11.5%
$-0.23vs$-0.26
Q1 25
+14.3%
$-0.24vs$-0.28
Q2 25
-10.7%
$-0.31vs$-0.28
Q3 25
-6.3%
$-0.34vs$-0.32
Q4 25
+11.8%
$-0.30vs$-0.34
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Mar 9, 2026 | $-0.34 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.34 | $-0.30 | +11.8% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.32 | $-0.34 | -6.3% | ✗ MISS |
Q2 2025 | May 7, 2025 | $-0.28 | $-0.31 | -10.7% | ✗ MISS |
Q1 2025 | Mar 10, 2025 | $-0.28 | $-0.24 | +14.3% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.26 | $-0.23 | +11.5% | ✓ BEAT |
Q3 2024 | Aug 5, 2024 | $-0.25 | $-0.21 | +16.0% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-0.28 | $-0.20 | +28.6% | ✓ BEAT |
Q1 2024 | Mar 19, 2024 | $-0.32 | $-0.21 | +34.4% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-0.42 | $-0.28 | +33.3% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-0.41 | $-0.36 | +12.2% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.37 | $-0.35 | +5.4% | ✓ BEAT |
Q1 2023 | Mar 14, 2023 | $-0.34 | $-0.31 | +8.8% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-0.28 | $-0.32 | -14.3% | ✗ MISS |
Q3 2022 | Aug 8, 2022 | $-0.25 | $-0.27 | -8.0% | ✗ MISS |
Q2 2022 | May 9, 2022 | $-0.22 | $-0.24 | -9.1% | ✗ MISS |
Q1 2022 | Mar 10, 2022 | $-0.22 | $-0.20 | +9.1% | ✓ BEAT |
Q4 2021 | Nov 9, 2021 | $-0.14 | $-0.21 | -50.0% | ✗ MISS |
Q3 2021 | Aug 9, 2021 | $-0.18 | $-0.14 | +22.2% | ✓ BEAT |
Latest News
Leerink Partners Upgrades Design Therapeutics to Outperform, Raises Price Target to $14
📈 PositiveBenzinga•Dec 3, 2025, 01:41 PM
Design Therapeutics shares are trading higher after RBC Capital upgraded the stock from Sector Perform to Outperform and raised its price target from $6 to $13.
📈 PositiveBenzinga•Nov 20, 2025, 05:50 PM
Design Therapeutics spikes as RBC upgrades on an eventful 2026
📈 PositiveSeeking Alpha•Nov 20, 2025, 04:57 PM
RBC Capital Upgrades Design Therapeutics to Outperform, Raises Price Target to $13
📈 PositiveBenzinga•Nov 20, 2025, 03:03 PM
RBC Capital Maintains Sector Perform on Design Therapeutics, Raises Price Target to $6
➖ NeutralBenzinga•Nov 6, 2025, 03:48 PM
Design Therapeutics Q3 EPS $(0.30) Beats $(0.34) Estimate
📈 PositiveBenzinga•Nov 5, 2025, 10:27 PM
Design Therapeutics Gets Clearance To Start Dosing DM1 Participants In Phase 1 Multiple-Ascending Dose Study Of DT-818 In Australia In H1 2026
📈 PositiveBenzinga•Nov 5, 2025, 09:31 PM
Frequently Asked Questions about DSGN
What is DSGN's current stock price?
Design Therapeutics, Inc. (DSGN) is currently trading at $9.68 per share. The stock has moved +7.44% today.
What is the analyst price target for DSGN?
The average analyst price target for DSGN is $14.50, based on 1 analyst.
What sector is Design Therapeutics, Inc. in?
Design Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is DSGN's market cap?
Design Therapeutics, Inc. has a market capitalization of $0.55 billion, making it a small-cap company.
Does DSGN pay dividends?
No, Design Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALT
Altimmune, Inc.
$3.90
Mkt Cap: $0.3B
ANNX
Annexon, Inc.
$5.17
Mkt Cap: $0.6B
AURA
Aura Biosciences, Inc.
$5.86
Mkt Cap: $0.4B
DMAC
DiaMedica Therapeutics Inc.
$8.48
Mkt Cap: $0.4B
ENGN
enGene Holdings Inc.
$8.69
Mkt Cap: $0.4B
GALT
Galectin Therapeutics Inc.
$4.38
Mkt Cap: $0.3B
IMAB
I-Mab
$3.95
Mkt Cap: $0.3B
KRRO
Korro Bio, Inc.
$7.88
Mkt Cap: $0.1B
LBRX
LB Pharmaceuticals Inc Common Stock
$21.07
Mkt Cap: $0.5B
RCKT
Rocket Pharmaceuticals, Inc.
$3.23
Mkt Cap: $0.3B
Explore stocks similar to DSGN for comparison